Archivio istituzionale della ricerca - Università dell'Insubria
Not a member yet
60118 research outputs found
Sort by
Immediate One-Stage Subcutaneous Breast Reconstruction without ADM: A Single-Center 6-Year Experience
No full textExpectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes
No full textObjective: To investigate to describe outcomes of conization or expectant management for women with persistent (>24 months) low-grade cervical intra-epithelial neoplasia.Methods: This is a retrospective analysis focusing on five-year outcomes after persistent, histologically confirmed, low-grade cervical intra-epithelial neoplasia undergoing conization or expectant management.Results: Charts of 219 women with persistent low-grade cervical lesions were retrieved. Overall, 98 (44.7%) and 121 (55.3%) women had conization and observation, respectively. Patients receiving conization were older than patients having observation (43 (range, 24-77) vs. 39 (range, 25-68) years; p=0.013). Focusing on the group of patients receiving conization, 16 (16.3%) women were diagnosed with CIN2+. The five-year risk of secondary conization was 5% (n=5). Focusing on patients having observation (n=121), 18 (14.8%) patients received conization, after a median of 16.5 (range, 6-30) months. Seven (5.8%) and 11 (9.1%) patients were diagnosed with persistent CIN1 and CIN2+, respectively. Not fully visible squamous-columnar junction at colposcopic examination (p=0.035) was associated with CIN2+ occurrence. No invasive cancer was observedConclusions: Conization for persistent low-grade cervical intra-epithelial neoplasia revealed "occult" CIN2+ in 16% of patients. However, expectant management appears safe and effective in this context, in women with fully visible squamous columnar junction. The decision between conization and expectant management should be discussed on an individual basis
Cicerone. La voce della Repubblica messa a tacere
No full textLa Repubblica agonizza sotto il peso delle guerre civili, mentre il potere è ormai nelle mani del secondo triumvirato. Tra ie vittime designate c'è Cicerone: orami sessantenne, dopo una brillante carriera, è solo, deluso, consapevole che la fine è vicina. La sua esecuzione non è solo la vendetta di un avversario, ma il simbolo della fine di un mondo
Recommendations on the health outcomes of infant formula supplemented with biotics by the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Special Interest Group on Gut Microbiota and Modifications
No full textFor many years, biotics (including probiotics, prebiotics, human identical milk oligosaccharides, synbiotics, and postbiotics) have been added to infant formula to influence the gut microbiota of formula-fed infants, aiming to bring it closer to that of breastfed infants. The Special Interest Group on Gut Microbiota and Modifications (SIG-GMM) of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) evaluated clinical outcomes from studies on biotic-supplemented infant formulas. A modified Delphi process was used to establish consensus on recommendations. This document is supported by separately published technical reviews, which synthesize the available evidence, analyze its limitations, and identify research gaps. ESPGHAN SIG-GMM concludes that infant formulas supplemented with one or more of the biotics evaluated so far fed to healthy infants do not raise safety concerns regarding growth, tolerance, and adverse effects. Based on available evidence, for some prebiotics (short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides), a weak recommendation in favor can be formulated because they soften stools by reducing stool consistency, and, to a lesser extent, increase stool frequency in presumed healthy infants. However, due to variability in study designs, intervention types, and measured outcomes, no clear conclusions can be drawn about their overall clinical benefits. Due to differences in interventions (e.g., duration, amount, and composition), inclusion criteria, and primary and secondary outcomes, for most biotics evaluated so far, no recommendations can actually be made “in favor” or “against.” This conclusion may reflect the limited data on specific biotics and outcomes because of the heterogeneity in the randomized controlled trials, rather than an actual lack of effect
Identifying Predictors for the Acquisition of Tolerance to Cow’s Milk Protein in Infants with Food Protein-Induced Allergic Proctocolitis (FPIAP): Multifactorial Analysis of Two Italian Cohorts
No full textBackground/Objectives: Food protein-induced allergic proctocolitis (FPIAP) is a non-IgE-mediated gastrointestinal food allergy. Although tolerance to the culprit food is usually achieved within the first year of life, late acquisition occurs and remains poorly predictable. This study aimed to analyze clinical characteristics and explore factors that may potentially function as predictors of late tolerance acquisition to cow’s milk (CM). Methods: We conducted a cross-sectional study at two Italian pediatric clinics (2020–2024), including infants diagnosed with FPIAP. Clinical, dietary, and immunological variables; onset and duration of rectal bleeding (visible blood in the stools); and time to CM tolerance were analyzed. Late tolerance was defined as acquisition after 19 months according to the distribution of tolerance achievement in our population. Statistical analyses included χ2, Mann–Whitney U, Spearman’s correlation, and logistic regression. Results: Ninety-four infants were included (median age at onset 2.9 months [IQR 1.9–4.7]); 58 (62%) were exclusively breastfed and 18 (19%) were born preterm (<37 completed weeks of gestation). CM was the culprit food in all cases; tolerance was achieved in all infants at a median age of 12 months. Family history of atopy and atopic dermatitis were reported in 44% and 19% of infants, respectively. Late CM tolerance was associated with preterm birth, fortification of human milk, early antibiotic exposure, growth faltering, and recurrent infections. Logistic regression identified family history of atopy (OR 5.4 [95% CI 1.2–25.4]; p = 0.031), atopic dermatitis (OR 8.2 [1.7–40.7]; p = 0.010), rectal bleeding >18 days before elimination diet (OR 5.9 [1.3–27.7]; p = 0.023), and IgE sensitization (OR 6.4 [1.2–35.0]; p = 0.034) as factors that may potentially function as predictors of late tolerance acquisition to CM. Conclusions: Identification of factors that may potentially function as predictors of late tolerance acquisition to CM in infants with FPIAP may help providing a personalized clinical management for these patients
Terrorizer: a novel algorithm for patent assignee name disambiguation
No full textThe problem of disambiguation of company names poses a significant challenge in extracting useful information from patents. This issue biases research outcomes as it mostly underestimates the number of patents attributed to companies, particularly multinational corporations which file patents under a plethora of names, including alternate spellings of the same entity and, eventually, companies' subsidiaries. To date, addressing these challenges has relied on labor-intensive dictionary based or string matching approaches, leaving the problem of patents' assignee harmonization on large datasets mostly unresolved. To bridge this gap, this paper describes the Terrorizer algorithm, a text-based algorithm that leverages natural language processing (NLP), network theory, and rule-based techniques to harmonize the variants of company names recorded as patent assignees. In particular, the algorithm follows the tripartite structure of its antecedents, namely parsing, matching and filtering stage, adding an original "knowledge augmentation" phase which is used to enrich the information available on each assignee name. We use Terrorizer on a set of 325'917 company names who are assignees of patents granted by the USPTO from 2005 to 2022. The performance of Terrorizer is evaluated on four gold standard datasets. This validation step shows two main advantages of Terrorizer: the first is that its performance is similar over different kinds of datasets, proving that our algorithm generalizes well. Second, it performs better than other existing algorithms currently used in patent data analysis. We use the Tree-structured Parzen Estimator (TPE) optimization algorithm for the hyperparameters' tuning. Our final result is a reduction in the initial set of names of over 42%. Finally, we show an application of our algorithm by analyzing patent transactions registered at the USPTO and identifying the most important intermediaries in the transaction network of ICT patents
L’irreale isola amena di Friedrich Leopold Von Stolberg: Die Insel, un’utopia mediterranea (1788)
No full textPro-Inflammatory Signaling in Dermal Fibroblasts: A Possible Role of Different Botulinum Toxin Formulations on IL-6 Expression
Full text linkBackground: Botulinum toxin type A (BoNT-A) formulations are extensively employed in aesthetic and therapeutic dermatology. However, their immunomodulatory and pro-inflammatory properties remain incompletely characterized, particularly concerning dermal fibroblasts. Aims: This study aimed to evaluate and compare the effects of three commercially available BoNT-A formulations-Bocouture, Vistabex, and Azzalure-on the expression of interleukin-6 (IL-6), a key pro-inflammatory cytokine, in cultured adult human dermal fibroblasts. Patients/methods: Human dermal fibroblasts were cultured in vitro and treated with increasing concentrations of Bocouture, Vistabex, and Azzalure. IL-6 expression was measured at 24, 48, and 72 h posttreatment using an enzyme-linked immunosorbent assay (ELISA). Cell viability was assessed by MTT assay to exclude cytotoxic effects. Each condition was tested in triplicate. Data were analyzed using one-way ANOVA with Bonferroni's multiple comparisons posttest. Results: Vistabex significantly increased IL-6 expression at multiple time points, with the most marked elevation observed at 0.5 U/mL after 24 h (p ≤ 0.0001). Conversely, Bocouture and Azzalure did not induce significant changes in IL-6 levels across all tested concentrations and time intervals. No formulation reduced fibroblast viability below 80%, confirming the absence of relevant cytotoxicity. Conclusions: These findings suggest a formulation-specific inflammatory response to BoNT-A in dermal fibroblasts, with Vistabex eliciting a notable upregulation of IL-6. The observed differences may be attributed to distinct structural or excipient-related properties and warrant further investigation to clarify their clinical implications, especially in patients with a predisposition to inflammatory skin responses
